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The integrin family of cell adhesion proteins promotes the attachment and migration of cells on the surrounding extracellular matrix
(ECM). Through signals transduced upon integrin ligation by ECM proteins or immunoglobulin superfamily molecules, this family of
proteins plays key roles in regulating tumour growth and metastasis as well as tumour angiogenesis. Several integrins play key roles in
promoting tumour angiogenesis and tumour metastasis. Antagonists of several integrins (a5b1, avb3 and avb5) are now under
evaluation in clinical trials to determine their potential as therapeutics for cancer and other diseases.
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During the last 10 years, novel insights into the mechanisms
that regulate cell survival as well as cell migration and invasion
have led to the development of novel integrin-based therapeutics
for the treatment of cancer. Several integrins play important
roles in promoting cell proliferation, migration and survival
in vitro and in vivo. Antagonists of these integrins suppress
cell migration and invasion of primary and transformed cells
and also induce apoptosis of primary cells. Integrin antagonists
also block tumour angiogenesis and tumour metastasis. Currently,
humanised antibody antagonists of integrins a5b1 and avb3
as well as peptide inhibitors of integrins avb3/avb5 are under
evaluation as angiogenesis-inhibiting therapeutics in cancer
clinical trials.
INTEGRINS REGULATE CELL SURVIVAL
AND MIGRATION
The invasion and survival of cells in vivo controls embryonic
development, angiogenesis, tumour metastasis and other physio-
logical processes (Aplin et al, 1998; Carmeliet and Jain, 2000; Hood
and Cheresh, 2002). Cell surface receptors for the extracellular
matrix (ECM), such as the integrins, play key roles in the
regulation of normal and tumour cell migration and survival. The
integrin family of cell adhesion proteins controls cell attachment to
the ECM (Figure 1). While some integrins selectively recognise
primarily a single ECM protein ligand (e.g., a5b1 recognises
primarily fibronectin), others can bind several ligands (e.g.,
integrin avb3 binds vitronectin, fibronectin, fibrinogen, denatured
or proteolysed collagen, and other matrix proteins). Several
integrins recognise the tripeptide Arg–Gly–Asp (e.g., avb3,
a5b1, aIIbb3), whereas others recognise alternative short peptide
sequences (e.g., integrin a4b1 recognises EILDV and REDV in
alternatively spliced CS-1 fibronectin). Inhibitors of integrin
function include function-blocking monoclonal antibodies, pep-
tide antagonists and small molecule peptide mimetics matrix
(reviewed in Hynes, 1992; Cheresh, 1993).
Although integrins mediate cellular adhesion to ECM proteins
found in intercellular spaces and basement membranes, they
also transduce intracellular signals that promote cell migration
(reviewed in Aplin et al, 1998; Schwartz and Shattil, 2000) as
well as cell survival (Meredith et al, 1993; Stromblad and Cheresh,
1996). However, unlike growth factor receptors, integrins have
no intrinsic enzymatic activity but activate signalling pathways
strictly by coclustering with kinases and adaptor proteins in
focal adhesion complexes. The association of integrins with
polyvalent or crosslinked ECM proteins clusters integrins
and their associated cofactors, thus activating integrin-regulated
signalling pathways. For example, integrin ligation suppresses
apoptosis by activating suppressors of apoptosis (Pankov
et al, 2003) and by inhibiting caspase activation (Stupack et al,
2001; Kim et al, 2002). Integrins also stimulate cell migration by
activating Rho and Rac GTPases (Ren et al, 1999) and
by anchoring actin filaments to the membrane. These adhesion
proteins promote cell cycle entry by stimulating expression
of cyclins (Assoian and Schwartz, 2001). Integrin ligation,
therefore, supports signal transduction cascades that promote
cell proliferation, cell survival and cell migration. In contrast,
inhibition of cell integrin–ligand interaction inhibits cell
migration (Kim et al, 2000a,b; Bakre et al, 2002) and proliferation
and induces apoptosis (Meredith et al, 1993; Boudreau et al, 1996;
Stupack et al, 2001; Bakre et al, 2002; Kim et al, 2002).
INTEGRIN ROLES IN CELL SURVIVAL
Studies from several groups showed that cell attachment is
required for the survival of normal cells (Meredith et al, 1993;
Stupack et al, 2001; Bakre et al, 2002). Complete loss of cell contact
with the substratum (e.g., suspension culture) or adhesion to a
nonspecific substratum such as poly-L-lysine induces apoptosis
(‘anoikis’) of primary cells such as fibroblasts (Meredith et al,
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epithelial cells (Frisch and Francis, 1994; Boudreau et al, 1996;
Stupack et al, 2001). In contrast, loss of contact with the
substratum does not necessarily kill tumour cells. Anchorage-
independent tumour cells survive loss of contact with the substrate
because they accumulate mutational changes in survival factors,
such as upregulation of Bcl 2 expression and/or loss of p53 activity,
which render the cells independent of integrin-mediated survival
signals.
Recent studies have shown that cell death can also occur when a
subset of integrins in a cell fail to bind their ECM ligands (Stupack
et al, 2001; Kim et al, 2002). For example, expression of avb3o r
a5b1 can inhibit cell survival in cells attached to the matrix
through other integrins (Stupack et al, 2001; Kim et al, 2002). The
expression of avb3 inhibits cell survival in cells attached to native
collagen through integrin a2b1 (Stupack et al, 2001). As integrin
avb3 does not bind native collagen, these results indicate that the
unligated integrin avb3 induces cell death. In a similar manner,
inhibition of integrin a5b1 activity with antibody antagonists
induces apoptosis of endothelial cells that are attached to
vitronectin through av integrins (Kim et al, 2002). In addition,
expression of dominant negative integrins (e.g., Tac-b3, the IL-2
receptor fused with the integrin beta 3 subunit cytoplasmic tail)
also inhibits survival by impairing normal integrin-mediated
survival signalling (Stupack et al, 2001). Integrin ligation
suppresses caspase 8 activation, while unligated integrins facilitate
caspase 8 activation in a stress response and death receptor
independent manner (Stupack et al, 2001; Kim et al, 2002).
Additional studies suggest that unligated integrins activate
membrane-associated protein kinase A (PKA), which itself can
activate caspase 8 in endothelial cells (Kim et al, 2002). Thus, in
normal cells, some integrins regulate survival when ligated and
induce apoptosis when unligated.
INTEGRIN ROLES IN CELL MIGRATION
While integrin ligation by the ECM positively regulates migration,
antagonising integrins inhibits cell migration. Although blocking
integrin ligation can prevent cell attachment to the ECM and thus
inhibit migration, recent studies show that antagonised integrins
actively inhibit signal transduction leading to cell migration (Kim
et al, 2000b). For example, the inhibition of integrin a5b1
negatively regulates fibroblast, endothelial cell and tumour cell
migration even when other integrin receptors for provisional
matrix proteins are ligated (Kim et al, 2000b). Antagonists of
integrin a5b1 suppress cell migration on vitronectin, but not cell
attachment to vitronectin, indicating that these antagonists affect
the migration machinery rather than integrin receptors for
vitronectin (Kim et al, 2000b). In fact, a5b1 antagonists activate
PKA, which then inhibits cell migration by disrupting the
formation of stress fibres (Kim et al, 2000b). Direct activation of
PKA by forskolin or by overexpression of the catalytic, active
subunit of PKA also inhibits cell migration (Bakre et al, 2002; Kim
et al, 2000b). Thus, integrins regulate cell migration by making
contact with the substratum and by promoting signal transduction
cascades that support migration.
INTEGRINS REGULATE ANGIOGENESIS
Angiogenesis is the process by which new blood vessels develop
from pre-existing vessels. The growth of new blood vessels
promotes embryonic development, wound healing and the female
reproductive cycle, and also plays a key role in the pathological
development of solid tumour cancers, haemangiomas, diabetic
retinopathy, age-related macular degeneration, psoriasis, gingivi-
tis, rheumatoid arthritis and possibly osteoarthritis and inflam-
matory bowel disease (reviewed in Carmeliet and Jain, 2000). New
advances in understanding the mechanisms regulating angiogen-
esis, such as those that promote cell migration and invasion, are
leading to the development of novel therapeutics for cancer.
Growth factors released by hypoxic tissues or pathological
tissues such as tumours stimulate new blood vessel growth. New
vessels grow by sprouting from pre-existing vessels (reviewed in
Carmeliet and Jain, 2000) or by recruitment of bone marrow-
derived endothelial progenitor cells (Asahara et al, 1997). While
growth factors and their receptors play key roles in angiogenic
sprouting, adhesion to the ECM also regulates angiogenesis
(Figure 2). Adhesion promotes endothelial cell survival (Kim
et al, 2002; Stupack and Cheresh, 2002), as well as endothelial cell
proliferation and motility (Kim et al, 2000a,b) during new blood
vessel growth. One ECM protein in particular, fibronectin, is
associated with vascular proliferation (Kim et al, 2000a,b); it is
expressed in provisional vascular matrices and provides prolif-
erative signals to vascular cells during wound healing, athero-
sclerosis and hypertension. Notably, fibronectin-null mice die
early in development from a collection of defects, which include an
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Figure 1 Molecules regulating angiogenesis. Growth factor receptors,
other tyrosine kinase receptors such as Tie-2, G-protein-coupled receptors
for angiogenesis modulating protein s such as interleukin-8 and parathyroid
hormone-related peptide (Bakre et al, 2002), as well as integrins play key
roles in the promotion of angiogenesis.
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Figure 2 Integrin family. Integrin alpha beta heterodimers can be
grouped into three subfamilies. Integrins a1b1, a2b1, a5b1, a4b1, avb3 and
avb5 (highlighted in blue) have been shown to play important roles in
regulating tumour angiogenesis.
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experimental studies showed that fibronectin regulates angiogen-
esis, as antibody inhibitors of fibronectin block angiogenesis (Kim
et al, 2000a).
Studies in experimental angiogenesis models and in mutant
mice indicate that several integrins play key roles in regulating
angiogenesis. Embryonic deletion of integrin a5b1 induces early
mesenchymal abnormalities, which include defects in the organi-
sation of the emerging vasculature (Yang et al, 1993; Goh et al,
1997) and defects in the ability of endothelial cells to form vessel-
like structures ex vivo (Taverna and Hynes, 2001; Francis et al,
2002). Similarly, loss of integrin a4b1 leads to aorta, heart and
other vascular malformations (Yang et al, 1995). Deletion of the av
subunit causes 80% of embryos to die early in development from
uncertain causes, while the few surviving embryos die a few hours
after birth with significant defects in brain development, including
failure of blood vessels to form properly (Bader et al, 1998). In
contrast, individual loss of the b3orb5 subunit during embryogen-
esis does not cause noticeable defects in the formation of the
cardiovascular system (Hodivala-Dilke et al, 1999; Huang et al,
2000). In fact, one study show that loss of the b3 or the b3 and b5
subunits promotes tumour angiogenesis (Reynolds et al, 2002).
These studies led to the controversial conclusion that the avb3/
avb5 integrins are not required for angiogenesis, but instead may
suppress angiogenesis. As many studies have shown that avb3 and
avb5 inhibitors block angiogenesis by inducing apoptosis in
proliferating endothelial cells (Brooks et al, 1994b), it is possible
that loss of the integrin-mediated death mechanism can lead to
enhanced angiogenesis (Cheresh and Stupack, 2002). In fact, loss
of either the b3o rb5 subunits does block angiogenesis induced by
the angiomatrix protein Del-1 (Zhong et al, 2003). Thus, integrins
appear to have diverse roles in the establishment of the
cardiovascular system, with integrin a5b1 clearly playing a major
role during development of the vascular system.
Studies in experimental models of angiogenesis also indicate
that several integrins can play important roles in regulating
angiogenesis in normal animals. The expression of both integrins
avb3 (Brooks et al, 1994a) and a5b1 (Kim et al, 2000a) are
significantly upregulated on endothelium during angiogenesis. The
expression of integrins avb3 and a5b1 partially controls angiogen-
esis; neither integrin is expressed by quiescent endothelium and
both are expressed in response to angiogenic growth factors
(Brooks et al, 1994a; Kim et al, 2000a,b). Their expression is
controlled by the transcription factor Hox D3 (Boudreau et al,
1997; Boudreau and Varner, 2003; Zhong et al, 2003). Hox D3 is a
Homeobox gene expressed by ECs that may regulate an angiogenic
switch. When expressed in vivo, Hox D3 promotes a haemangio-
ma-like proliferation of blood vessels (Boudreau et al, 1997; Zhong
et al, 2003); this transcription factor promotes the expression of
integrin avb3, a5b1 and uPA, molecules with established roles in
angiogenesis. Thus, Hox D3 may provide a switch to activate a
program of angiogenesis. Once integrins a5b1 and avb3 are
expressed, angiogenesis depends on each integrin as antagonists of
each can block angiogenesis in vivo (Brooks et al, 1994a,b; Kim
et al, 2000a). Antibody and peptide antagonists of integrins avb3
and a5b1 inhibit growth factor as well as tumour angiogenesis,
tumour growth and tumour metastasis (Brooks et al, 1994a,b;
Carron et al, 1998; Kim et al, 2000a; Stoeltzing et al, 2003). These
studies indicate that these integrins function in part by promoting
survival in proliferating endothelial cells in vivo (Brooks et al,
1994b; Kim et al, 2002). Studies of the signals transduced when
integrins are antagonised indicate that unligated integrins activate
PKA, which then activates caspase 8 and induces apoptosis (Bakre
et al, 2002; Kim et al, 2002).
In addition, other integrins have been shown to regulate
angiogenesis. Integrin avb5 promotes VEGF-, but not bFGF-,
mediated angiogenesis (Friedlander et al, 1995). Integrin receptors
for laminin and collagen also play roles in regulating blood vessel
formation as antagonists of a2b1 and a1b1 suppressed VEGF-
mediated angiogenesis (Senger et al, 1997). Thus, integrins play
key roles in regulating tumour angiogenesis, and integrin
antagonists hold promise as future therapeutics for cancer.
INTEGRINS PLAY ROLES IN TUMOUR INVASION
AND METASTASIS
Tumour metastasis promotes the spread of tumours to local and
distant sites away from primary tumours. Metastasis is the leading
cause of the morbidity and mortality associated with cancer.
Tumour cells isolated from metastases are highly migratory and
invasive. Therefore, understanding the mechanisms regulating cell
migration may be helpful in developing new modes of therapy for
metastatic cancer.
Increased levels of expression of integrins avb3 is closely
associated with increased cell invasion and metastasis (Felding-
Habermann et al, 2002). Notably, integrin avb3 is expressed on
invasive melanoma but not benign nevi or normal melanocytes
(Gehlsen et al, 1992). Additionally, increased avb3 expression
levels correlate with increased rates of melanoma metastases (Nip
et al, 1992).
Integrin a6 expression is also significantly upregulated in
numerous carcinomas, including head and neck cancers and
breast cancer (Garzino-Demo et al, 1998; Mercurio et al,
2001; Ramos et al, 2002). Integrin a6b4 expression enhances
tumour cell invasiveness and metastasis, particularly in breast
carcinomas (Mercurio et al, 2001; Ramos et al, 2002). Thus,
antagonists of these integrins may be useful to prevent the spread
of tumour cells.
INTEGRIN INHIBITORS AS THERAPEUTIC AGENTS
FOR CANCER
Several integrin inhibitors are currently under investigation as
therapeutics for cancer. Antibody and peptide inhibitors
of integrins avb3 and avb5 (for review, see Kerr et al, 2002) and
of a5b1 are currently in clinical trials for the inhibition of
angiogenesis in cancer. A humanised anti-avb3 antibody, Vitaxin,
is currently in Phase II trials for cancer (Gutheil et al, 2000;
Patel et al, 2001; Posey et al, 2001; Mikecz, 2000), while a
humanised anti-a5b1 antibody is in Phase I trials for
cancer (Varner, personal communication; www.pdl.com). A
cyclic peptide inhibitor of integrin avb3/avb5, Cilengitide,
is in Phase I/II trials for glioblastoma and other cancers
(Burke et al, 2002; Eskens et al, 2003; Smith, 2003). Other
promising integrin a5b1- and avb3-blocking peptides
with antitumour angiogenesis and tumour metastasis activities
are currently in preclinical development (Carron et al, 1998;
Reinmuth et al, 2003; Stoeltzing et al, 2003). As Avastin, the
antibody inhibitor of VEGF, has recently shown promise as a
therapeutic for colon cancer in Phase III clinical trials (Fernando
and Hurwitz, 2003), these integrin-based antiangiogenesis ther-
apeutics hold great promise as powerful therapeutics for the
treatment of cancer.
CONCLUSION
The studies reviewed here indicate that integrin promote cellular
migration and survival in tumour and primary cells. Antagonists
of integrins avb3, a5b1, avb5 and a6b4 show great promise as
potential inhibitors of tumour growth and metastasis as well as
tumour angiogenesis. Clinical trials are currently underway to
evaluate inhibitors of integrin avb3, avb5 and a5b1 for their
usefulness in the treatment of cancer.
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